Shallcross Steven A's Form 4 filing
Theriva Biologics, Inc. (TOVX) · filed Jun 8, 2023
- Accession no.
- 0001104659-23-069136
- Filed
- Jun 8, 2023
- Trade date
- Jun 7, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $9.66K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shallcross Steven ACIK 0001263501 | Director, Officer (CEO and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 7, 2023 | Common Stock | PPurchaseAcquired | +14,000 | $0.69 | +$9,660 | 250,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.